Amanta Healthcare Limited was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership firm ‘Marck Parenterals (India)’ under Part IX of the Companies Act, 1956 and received the Certificate for Commencement of Business on January 06, 1995. The name of the company was changed to ‘Marck Biosciences Limited’ pursuant to a special resolution passed by its shareholders on October 29, 2005, and a fresh certificate of incorporation issued by the Registrar of Companies, Gujarat, at Ahmedabad, dated November 2, 2005. Subsequently, the name of the company was changed to ‘Amanta Healthcare Limited’ pursuant to a special resolution passed by its shareholders on June 12, 2014, and a fresh certificate of incorporation dated June 24, 2014 issued by the Registrar of Companies, Gujarat, at Ahmedabad.Amanta Healthcare is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal (ABFS) and Injection Strech Blow Moulding (ISBM) technology.

It manufactures large volume parenterals (LVPs) and small volume parenterals (SVPs) in therapeutic segments. In addition to that, it also manufacturers medical devices. It manufactures fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc.

in medical device segment. It offers wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume.It manufactures diverse generics product portfolio of various products and markets them under its own brands in the Indian market through a network of many distributors and stockists. It sells its products in various countries including the Africa, Latin America, UK and the Rest of the world.

Its international sales business covers, advanced market countries and emerging market countries. Its product partnering business includes commercial large-scale manufacturing of generic products. It also undertakes manufacturing under loan license agreements with its customers.

Under product partnering model, it has developed relationships across the Indian pharmaceutical industry and some of its key customers.Business area of the companyThe company is engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with ABFS and ISBM technology. It manufactures large volume parenterals LVPs and SVPs in therapeutic segments.Products of the companyFluid TherapySodium Chloride Intravenous Infusion B.P. (9g / L)Sodium Chloride Infusion U.S.P.

(0.45 % w/v)Glucose Intravenous Infusion B.P. (50g / L)Glucose Intravenous Infusion B.P. (100 gm/lt)Sodium Chloride (4.5 gm/lt) Glucose (50 gm/lt) Intravenous Infusion B.P.Sodium Chloride (9 gm/lt) Glucose (50 gm/lt) Intravenous Infusion B.P.Compound Sodium Lactate Intravenous Infusion B.P.

(Ringer Lactate Infusion)Multiple electrolyte MElectrolyte P InfusionDextrose 20+ Multiple electrolyteMultiple electrolyte Dextrose InjectionDextrose 25%FormulationsCiprofloxacin Injection U.S.P. (0.2% w/v)Metronidazole Intravenous Infusion B.P. (5g / L)Fluconazole Infusion (0.2% w/v)Levofloxacin Infusion (500mg / 100mL)Mannitol Intravenous Infusion B.P.

(20% w/v)Paracetamol Infusion (10mg / mL)Moxifloxacin Intravenous Infusion (400mg /100mL)Linezolid Intravaneous Infusion (200mg/100mL)Ofloxacin Infusion (0.2% w/v)Ornidazole Infusion (500mg / 100mL)Tinidazole InfusionSodium Chloride Hypertonic Injection (3% w/v)DiluentsSterilized Water for Injections B.P. / U.S.P.Sodium Chloride Injection B.P. (0.9% w/v)Lidocaine Injection B.P.

(1 % w/v)Respiratory SolutionsSalbutamol Respirator Solution (2.5mg / 2.5mL)Salbutamol + Ipratropium Respirator Solution (2.5mg + 500 mcg / 2.5mL)Levosalbutamol + Ipratropium Respirator Solution (1.25 mg + 0.5 mg)InjectionsLidocaine Injection B.P. (1% w/v)Potassium Chloride Injection (15.0% w/v)Magnesium Sulfate Injection U.S.P. (50% w/v)Glucose Injection B.P.

(40% w/v)Ophthalmics (FFS)Ciprofloxacin Ophthalmic Solution U.S.P. (0.3% w/v)Timolol Maleate Eye Drops B.P. (0.5% w/v 0.25% w/v)Gentamicin Eye Drops B.P.

(0.3% w/v)Gentamicin Sulphate (0.3% base) Dexamethasone (0.1% w/v) Eye / Ear DropsTobramycin (0.3% w/v) + Dexamethason (0.1% w.v) Eye dropsMoxifloxacin Eye DropsMedical Devices (CE Mark)Sodium Chloride Eye Wash Wound CleaningCarboxymethyl Cellulose Sodium Eye Drops (0.5 % w/v)Hypermellose Eye Drops (0.5v% w/v)Sodium Hyaluronate 0.3% w/v Eye DropsIrrigation SolutionsBalance Sault SolutionsSurgicalIntravenous (IV Set)Awards, accreditations and recognition2022: Received ISO 13485:2016/ EN ISO 13485:2016 accreditation for its management system for the design, development, manufacturing, distribution and sales of sterile ophthalmic ocular lubricant drops and sterile irrigation solutions.2023: Received ISO 45001:2018, ISO 14001:2015 and ISO 9001:2015 accreditation for its management system for the manufacture and dispatch of small and large volume parenterals.History and milestones1994: Converted in a Public Limited Company.1997: Started implementation of Large Volume Parenterals (LVP) project for Formulations, Fluid Therapy Irrigation Solution1998: Commencement of L-1 in Block A.2002: Launched a specialised production line ‘LVP Line II’ for the manufacture of Large Volume Parenterals in Kheda, Gujarat.2005: Launched a specialised production line ‘SVP Line I’ for the manufacture of Small Volume Parenterals in Kheda, Gujarat.2007: Added L-III Large Volume Parenterals Facility for 500 ml products in Block -A.2008: Launched a specialised production line “SVP line II” for the manufacture of Small Volume Parenterals in Kheda, Gujarat.2008: Approval from The National Pharmaceutical Control Bureau - Malaysia (a PIC member).2021: Launched a specialised production line ‘SteriPort -Debottlenecking’.2023: Received WHO- GMP certification for Manufacturing facility at Kheda, Gujarat.2024: Got CE Mark Certification for Eye Wash Solutions.2024: Manufacturing out of seven active production lines including SVP and LVP.2024: Granted permission to manufacture and market the product named Linezolid I.V. injection (Domestic).